Search hospitals > Missouri > Saint Louis
Mercy Hospital Saint Louis
Claim this profileSaint Louis, Missouri 63141
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Brain Tumor
Conducts research for Breast cancer
511 reported clinical trials
5 medical researchers
Summary
Mercy Hospital Saint Louis is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Brain Tumor, Breast cancer and other specialties. Mercy Hospital Saint Louis is involved with conducting 511 clinical trials across 682 conditions. There are 5 research doctors associated with this hospital, such as Jay W Carlson, Robin D. Hanson, Dan-Arin Silasi, MD, and Khaled Awad.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Jay W CarlsonMercy Hospital Saint Louis6 years of reported clinical research
Expert in Breast Cancer
Expert in Lung Cancer
219 reported clinical trials
295 drugs studied
Robin D. HansonMercy Hospital Saint Louis8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
53 reported clinical trials
104 drugs studied
Dan-Arin Silasi, MDDavid C. Pratt Center3 years of reported clinical research
Studies Cervical Cancer
Studies Ovarian Cancer
2 reported clinical trials
6 drugs studied
Khaled AwadMercy Hospital St. Louis4 years of reported clinical research
Studies Ventricular Tachycardia
Studies Heart Failure
2 reported clinical trials
3 drugs studied
Clinical Trials running at Mercy Hospital Saint Louis
Lung Cancer
Ovarian Cancer
Prostate Cancer
Breast Cancer
Esophageal cancer
Cancer
Breast cancer
Multiple Myeloma
Kidney Cancer
Bladder Cancer
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Mercy Hospital Saint Louis?
Mercy Hospital Saint Louis is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Brain Tumor, Breast cancer and other specialties. Mercy Hospital Saint Louis is involved with conducting 511 clinical trials across 682 conditions. There are 5 research doctors associated with this hospital, such as Jay W Carlson, Robin D. Hanson, Dan-Arin Silasi, MD, and Khaled Awad.
Where is Mercy Hospital Saint Louis located?
**Mercy Hospital St. Louis Location:**
- Address: 615 S New Ballas Rd, St. Louis, MO.
- Directions: Located at the intersection of I-270 and I-64/US 40. From I-64/US 40, take exit 29A for I-270 N, then exit 1B for I-270 S/I-64 E toward St. Louis. Continue on I-64 E, take exit 35 for New Ballas Rd, and turn left. The hospital is on the right.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Mercy Hospital Saint Louis, contact the Mercy Health Care Financial Assistance (HFA) department at (513) 956-3729 or visit their website. For inquiries, call Mercy Health customer service at 855-420-7900. To request a hard copy of the financial assistance application, call 608.741.7630 or 866.269.7115, visit the main reception or MercyCare Building (Monday-Friday, 8 am-4:30 pm), contact via MyChart, or email custserv@mhemail.org.
What insurance does Mercy Hospital Saint Louis accept?
Mercy Hospital Saint Louis accepts a wide range of health insurance types, including commercial, Medicare, and Medicaid, from numerous local and national carriers. It's crucial to verify coverage and restrictions with your insurance provider before scheduling visits. Additionally, Essence Healthcare's Medicare Advantage plans are now part of Mercy Hospital Saint Louis's provider network, enhancing access to high-quality care for members in the St. Louis area.
What awards or recognition has Mercy Hospital Saint Louis received?
Mercy Hospital Saint Louis, located in Saint Louis, Missouri, was awarded the Cutting Edge Award by the St. Louis Business Journal in 2019 for innovative centralization of research activities. It has also been recognized as one of the top five large U.S. health systems for four consecutive years by IBM Watson Health.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.